Press Release: STADA invests more than €85m in Saudi Arabia manufacturing hub
Ein Dokument
mehr
Storys zum Thema Pharmakologie
- Sprache:
- Medien:
- Zeitraum:
- Zeitraum:Gesamt
Press Release: STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi
STADA and Bio-Thera receive European Marketing Authorization for Gotenfia, a Biosimilar to Simponi - European Commission grants approval for Gotenfia®, a golimumab biosimilar to Simponi® that was developed by Bio-Thera and will be marketed by STADA ...
Ein DokumentmehrPress Release: Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion
Golimumab biosimilar Gotenfia from STADA and Bio-Thera receives positive CHMP opinion - Positive opinion from European Medicines Agency supports approval for golimumab biosimilar Gotenfia® developed by Bio-Thera and to be marketed by STADA - ...
Ein DokumentmehrPress Release: STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe
STADA obtains approvals to bring denosumab biosimilars in bone-health and oncology to patients in Europe - European Commission approves STADA’s Kefdensis® and Zvogra® denosumab biosimilars for all indications of reference medicines Prolia® and ...
3 DokumentemehrPress Release: STADA is in top 3% on pharma sustainability, Morningstar Sustainalytics assessment confirms
Ein DokumentmehrPress release: STADA sees strong sales and earnings growth in H1
Ein Dokumentmehr
Press release: Bio-Thera and STADA Extend Biosimilars Alliance to Tocilizumab
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN WHOLE OR IN PART, IN OR INTO THE UNITED STATES OF AMERICA, AUSTRALIA, CANADA OR JAPAN OR ANY OTHER JURISDICTION IN WHICH SUCH DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL OR REQUIRE REGISTRATION OR ANY OTHER MEASURES. Press release ...
Ein DokumentmehrPress Release : STADA brings in Henshaw from Biogen to head Specialty as Kim leads Western Europe
Ein DokumentmehrPress Release: STADA’s continued, resilient growth leads to record earnings in Q1
Ein Dokumentmehr- 3
Press Release STADA’s growth journey continues in 2024 - Significant increase in sales and profits - Growing ahead of the market
Ein Dokumentmehr Event Announcement: VIROFIGHT Hybrid Symposium
Ein Dokumentmehr- 2
Fundació Puigvert validates a new tool capable of selecting the most suitable antibiotic for uncomplicated urinary tract infections within 45 minutes.
Ein Dokumentmehr
- 2
Record financing rounds at the Munich biotech hub
Ein Dokumentmehr Press release: STADA continues strong growth journey in the first half of 2024
Ein DokumentmehrPress release: Alvotech and STADA add to strategic alliance through denosumab partnership
Alvotech and STADA add to strategic alliance through denosumab partnership - STADA assumes marketing license for Alvotech’s proposed biosimilar referencing Prolia®/Xgeva® (denosumab) in Europe, including Switzerland and the UK, as well as rights in selected markets in Central Asia and the Middle ...
Ein DokumentmehrPress release: STADA welcomes CHMP positive opinion on extending indication for Kinpeygo
STADA welcomes CHMP positive opinion on extending indication for Kinpeygo - The CHMP adopted a positive opinion recommending a change to the terms of the marketing authorization of Kinpeygo for the treatment of adults with primary immunoglobulin A, now covering patients with a UPCR of ≥0.8 g/g - ...
Ein DokumentmehrPress release: Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK
Bio-Thera and STADA Reach Exclusive Agreement for BAT2506, a Proposed Golimumab Biosimilar, in the EU and UK - Bio-Thera and STADA have reached an exclusive commercialization and license agreement for BAT2506, a biosimilar candidate to Simponi® ...
Ein DokumentmehrcanSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr
- 3
canSERV invites applications for "Revolutionising Cancer Patient Care"
Ein Dokumentmehr Press release: STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey
STADA reduces carbon emissions and increases its renewable energy supply on sustainability journey - Total carbon emissions by STADA reduced by 25% between 2020 and 2023 - Around 45% of STADA’s electricity consumption now comes from renewable ...
Ein DokumentmehrPress release: STADA continues with double-digit sales and profit growth in 2023
Ein Dokumentmehr- 2
Press release : People with Parkinson’s experience variations in effects of oral medicines, but lack advice, international survey reveals
Ein Dokumentmehr - 2
The start-up Eisbach Bio in the IZB near Munich receives 6.7 million euros from the Bavarian state government for the development of a COVID-19 therapeutics
Ein Dokumentmehr - 2
COVID-19: Start-up Eisbach Bio at the IZB receives EUR 8 million government grant
Ein Dokumentmehr
- 7
Biotech start-ups at the IZB close deals worth more than 140 million EUR in the first half of 2021
Ein Dokumentmehr - 2
Lindis Biotech develops immunotherapy against bladder cancer
Ein Dokumentmehr Origenis founds biotech company Neuron23 in Silicon Valley together with star investor Kleiner Perkins
Ein Dokumentmehr- 3
World Cancer Day: Start-ups at the IZB develop innovative cancer drugs and diagnostic tools
Ein Dokumentmehr - 5
Commemorative publication for the 25th anniversary of the IZB presents 70 profiles and visions of successful biotech start-ups
Ein Dokumentmehr KOPIE VON: Inspirational talks form SIRION Biotech, CLS Behring and the German Accelerator at the 13th Biotech Press Lounge at the IZB
Ein Dokumentmehr
12Nächste